These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33281002)

  • 1. Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment.
    Antonio M; Raffaghelli M; Maggio RM
    J Pharm Biomed Anal; 2021 Feb; 194():113786. PubMed ID: 33281002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Polymorphic Purity of Rifampicin in Double and Triple-Drug Fixed-Dose Combination Products.
    Antonio M; Raffaghelli M; Maggio RM
    J Pharm Sci; 2024 Apr; 113(4):930-936. PubMed ID: 37783271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S; Mannava MKC; Nangia A
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of chemometrics to compare NIR and HPLC for the simultaneous determination of drug levels in fixed-dose combination tablets employed in tuberculosis treatment.
    Teixeira KSS; da Cruz Fonseca SG; de Moura LCB; de Moura MLR; Borges MHP; Barbosa EG; De Lima E Moura TFA
    J Pharm Biomed Anal; 2018 Feb; 149():557-563. PubMed ID: 29197297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution testing of isoniazid, rifampicin, pyrazinamide and ethambutol tablets using near-infrared spectroscopy (NIRS) and multivariate calibration.
    de Oliveira Neves AC; Soares GM; de Morais SC; da Costa FS; Porto DL; de Lima KM
    J Pharm Biomed Anal; 2012 Jan; 57():115-9. PubMed ID: 21908131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of mefenamic acid polymorphs in commercial tablets using chemometric coupled to MIR and NIR spectroscopies. Prediction of dissolution performance.
    Antonio M; Maggio RM
    J Pharm Biomed Anal; 2018 Feb; 149():603-611. PubMed ID: 29202439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of near infrared spectroscopy in rapid and simultaneous determination of essential components in five varieties of anti-tuberculosis tablets].
    Teng LS; Wang D; Song J; Zhang YB; Guo WL; Teng LR
    Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Aug; 28(8):1814-8. PubMed ID: 18975810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the spontaneous polymorphic transition of pyrazinamide γ form at room temperature by co-spray drying with 1,3-dimethylurea.
    Baaklini G; Dupray V; Coquerel G
    Int J Pharm; 2015 Feb; 479(1):163-70. PubMed ID: 25556055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
    Bellur Atici E; Karlığa B
    J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics.
    Suárez-González J; Santoveña-Estévez A; Soriano M; Fariña JB
    Drug Dev Ind Pharm; 2020 Feb; 46(2):309-317. PubMed ID: 31944867
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimization of a reversed-phase-high-performance thin-layer chromatography method for the separation of isoniazid, ethambutol, rifampicin and pyrazinamide in fixed-dose combination antituberculosis tablets.
    Shewiyo DH; Kaale E; Risha PG; Dejaegher B; Smeyers-Verbeke J; Vander Heyden Y
    J Chromatogr A; 2012 Oct; 1260():232-8. PubMed ID: 22981506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compatibility Between Four Anti-TB Drugs and Tablet Excipients Determined By Microcalorimetry.
    Aucamp M; Liebenberg W; Okaecwe T; Geldenhuys M; Stieger N
    Pharmazie; 2019 Jun; 74(6):350-351. PubMed ID: 31138372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An explanation for the physical instability of a marketed fixed dose combination (FDC) formulation containing isoniazid and ethambutol and proposed solutions.
    Bhutani H; Mariappan TT; Singh S
    Drug Dev Ind Pharm; 2004 Jul; 30(6):667-72. PubMed ID: 15285340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of mebendazole polymorphs in pharmaceutical raw materials using near-infrared spectroscopy.
    da Silva VH; Gonçalves JL; Vasconcelos FV; Pimentel MF; Pereira CF
    J Pharm Biomed Anal; 2015 Nov; 115():587-93. PubMed ID: 26320077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.